MedTrace Logo

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

NCT01647568 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 715

Last updated 2012-07-23

No results posted yet for this study

Summary

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy.

Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Conditions

  • Post-polypectomy Bleeding
  • Anti-platelet Therapy
  • Colonoscopy

Sponsors & Collaborators

  • Dallas VA Medical Center

    lead FED

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01647568 on ClinicalTrials.gov